返回 Agenda
S34 : Pediatric Drug Development and Evidence Strategies in Japan in the Era of Global Clinical Trials
Session Chair(s)
Kazuhiro Kanmuri, PHD
Executive Officer, Head of Development Div.
Tanabe Pharma Corporation, Japan
Speaker(s)
Satoshi Shoji, PHD
Pfizer R&D Japan G.K., Japan
Manager, Pharmacometrician, Clinical Pharmacology
Takashi Nagakubo, PHD
Glaxosmithkline K.K., Japan
Principal Statistician, Biostatistics
Foteini Strimenopoulou, PHD
UCB Pharma, United Kingdom
Principal Statistician
Satrajit Roychoudhury, PHD
Pfizer, United States
Executive Director, Statistical Research and Innovation
Reiko Nakashima
Pharmaceuticals and Medical Devices Agency (PMDA), Japan
Reviewer, Office of New Drug I